Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX-101 for Maintenance in Severe Bipolar Depression with Suicidality
NCT03396068Phase 3Active, not recruiting
- Sponsor
- NRx Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of d-cycloserine + lurasidone in bipolar disorder (BD), suicidal ideation, sponsored by NRx Pharmaceuticals. Started Dec 2019; status: active, not recruiting.
02
Drugs
d-cycloserine + lurasidone
03
Conditions
bipolar disorder (BD)suicidal ideation
Beyond the preview
Go deeper on NCT03396068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396068.